<DOC>
	<DOCNO>NCT02724332</DOCNO>
	<brief_summary>To evaluate clinical effect rapamycin combine TACE early-stage HCC overexpression ASPH radical surgery use randomize control study provide new anti-recurrence treatment HCC patient operation .</brief_summary>
	<brief_title>Adjuvant Anti-Recurrence Treatment With Rapamycin Early-stage HCC</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>1 . Via clinical diagnosis confirm primary liver cancer 2 . Pathological evidence HCC 3 . Estimate tumor gain treatment cure operation 4 . No evidence extrahepatic metestasis 5. liver function ：ChildPugh A/B 6 . BCLC stage：0/1；TNM stage：Ⅰ 1. reject attend； 2. impossible come hospital physical examination regularly . 3. cancer epitome、seed focus、lymph node distant metastasis 4 . Blood clot function hindrance ; 5 , Patients disease may affect treatment mention .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Aspartate beta hydroxylase</keyword>
	<keyword>transcatheter arterial chemoembolization</keyword>
</DOC>